New hope for hard-to-treat cancers with gene amplification?
NCT ID NCT04439201
First seen Mar 17, 2026 · Last updated Apr 30, 2026 · Updated 8 times
Summary
This study tests a drug called palbociclib in people with advanced cancers that have extra copies of certain genes (CCND1, 2, or 3). The drug blocks proteins that help cancer grow. Researchers want to see if it can shrink tumors or stop them from getting worse. About 40 adults with solid tumors or lymphomas that haven't responded to other treatments are taking part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
ECOG-ACRIN Cancer Research Group
Philadelphia, Pennsylvania, 19103, United States
Conditions
Explore the condition pages connected to this study.